Principal Financial Group Inc Myriad Genetics Inc Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Myriad Genetics Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 428,023 shares of MYGN stock, worth $6.51 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

428,023

Previous 449,606 4.8%

Holding current value

$6.51 Million

Previous $11 Million 6.52%

% of portfolio

0.01%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$23.97 - $28.6 $517,344 - $617,273	-21,583 Reduced 4.8%	428,023 $11.7 Million
Q2 2024 Jul 29, 2024	SELL	$17.98 - $25.47 $354,637 - $502,370	-19,724 Reduced 4.2%	449,606 $11 Million
Q1 2024 Apr 29, 2024	SELL	$17.59 - $23.59 $42,321 - $56,757	-2,406 Reduced 0.51%	469,330 $10 Million
Q4 2023 Feb 07, 2024	BUY	$13.91 - $21.32 $273,428 - $419,087	19,657 Added 4.35%	471,736 $9.03 Million
Q3 2023 Nov 02, 2023	SELL	$15.99 - $23.22 $347,142 - $504,106	-21,710 Reduced 4.58%	452,079 $7.25 Million
Q2 2023 Aug 07, 2023	SELL	$17.56 - $23.76 $473,979 - $641,329	-26,992 Reduced 5.39%	473,789 $11 Million
Q1 2023 May 09, 2023	SELL	$15.26 - $23.75 $92,261 - $143,592	-6,046 Reduced 1.19%	500,781 $11.6 Million
Q4 2022 Feb 09, 2023	SELL	$14.51 - $20.99 $168,374 - $243,567	-11,604 Reduced 2.24%	506,827 $7.35 Million
Q3 2022 Nov 09, 2022	SELL	$18.21 - $27.88 $383,411 - $587,013	-21,055 Reduced 3.9%	518,431 $9.89 Million
Q2 2022 Aug 10, 2022	SELL	$16.45 - $25.88 $575,947 - $906,110	-35,012 Reduced 6.09%	539,486 $9.8 Million
Q1 2022 May 09, 2022	SELL	$22.67 - $28.01 $568,495 - $702,406	-25,077 Reduced 4.18%	574,498 $14.5 Million
Q4 2021 Feb 09, 2022	SELL	$24.13 - $32.63 $1.12 Million - $1.51 Million	-46,286 Reduced 7.17%	599,575 $16.5 Million
Q3 2021 Nov 09, 2021	SELL	$29.97 - $36.66 $46,903 - $57,372	-1,565 Reduced 0.24%	645,861 $20.9 Million
Q2 2021 Aug 10, 2021	BUY	$25.39 - $32.61 $949,078 - $1.22 Million	37,380 Added 6.13%	647,426 $19.8 Million
Q1 2021 May 10, 2021	BUY	$19.92 - $31.6 $263,442 - $417,910	13,225 Added 2.22%	610,046 $18.6 Million
Q4 2020 Feb 08, 2021	SELL	$12.16 - $19.77 $761,361 - $1.24 Million	-62,612 Reduced 9.49%	596,821 $11.8 Million
Q3 2020 Nov 06, 2020	BUY	$11.25 - $14.75 $321,232 - $421,171	28,554 Added 4.53%	659,433 $8.6 Million
Q2 2020 Aug 05, 2020	BUY	$10.69 - $16.49 $468,638 - $722,905	43,839 Added 7.47%	630,879 $7.15 Million
Q1 2020 May 12, 2020	SELL	$9.78 - $29.53 $227,355 - $686,483	-23,247 Reduced 3.81%	587,040 $8.4 Million
Q4 2019 Feb 05, 2020	SELL	$20.93 - $35.1 $340,782 - $571,498	-16,282 Reduced 2.6%	610,287 $16.6 Million
Q3 2019 Nov 13, 2019	BUY	$22.08 - $47.08 $113,049 - $241,049	5,120 Added 0.82%	626,569 $17.9 Million
Q2 2019 Aug 12, 2019	SELL	$22.67 - $35.0 $122,622 - $189,315	-5,409 Reduced 0.86%	621,449 $17.3 Million
Q1 2019 May 10, 2019	SELL	$26.93 - $34.7 $486,086 - $626,335	-18,050 Reduced 2.8%	626,858 $20.8 Million
Q4 2018 Feb 14, 2019	BUY	$27.23 - $45.56 $822,808 - $1.38 Million	30,217 Added 4.92%	644,908 $18.7 Million
Q3 2018 Nov 14, 2018	BUY	$37.57 - $50.34 $1.19 Million - $1.59 Million	31,651 Added 5.43%	614,691 $28.3 Million
Q2 2018 Aug 13, 2018	SELL	$27.75 - $40.17 $18,370 - $26,592	-662 Reduced 0.11%	583,040 $0
Q1 2018 May 14, 2018	BUY	$28.83 - $41.01 $605,458 - $861,251	21,001 Added 3.73%	583,702 $17.2 Million
Q4 2017 Feb 13, 2018	BUY	$28.45 - $37.14 $1.08 Million - $1.41 Million	37,966 Added 7.24%	562,701 $19.3 Million
Q3 2017 Nov 02, 2017	BUY	$24.01 - $36.2 $12.6 Million - $19 Million	524,735	524,735 $19 Million

Others Institutions Holding MYGN

# of Institutions

253

Shares Held

90.9M

Call Options Held

100K

Put Options Held

34K

View Full List

About MYRIAD GENETICS INC

Ticker MYGN
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 80,634,800
Market Cap $1.23B
Description
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...

More about MYGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Myriad Genetics Inc Transaction History